Michael Weinstein

First Solar, Inc. (NASDAQ: FSLR) shares have gained 10 percent quarter-to-date, and despite expecting in-line first-quarter results, Credit Suisse is bearish on the solar manufacturer.  The Analyst Analyst Michael Weinstein reiterated an Underperform on First Solar with a $57 price target...

When the stock market becomes unpredictable and volatile like it did last week, traders often turn to pair trades to mitigate risk. One Wall Street analyst sees a pair of solar stocks that could form the basis for a solid 2018 pair trade. The Analyst Credit Suisse analyst Michael Weinstein has an...

The potential implications of tax legislation and regulatory headwinds on the gas and electric utility Black Hills Corp (NYSE: BKH) led to a downgrade from Credit Suisse on Tuesday.  The Analyst Analyst Michael Weinstein downgraded Black Hills from Outperform to Neutral and lowered his...

The medical technology space for the most part benefited throughout 2017 and heading into 2018 some Wall Street analysts remain bullish. The Analyst JPMorgan's Michael Weinstein. The Thesis 2017 was a positive year for the MedTech space and was able to overcome multiple challenges,...

NextEra Energy Inc (NYSE: NEE) managed to post better-than-expected third quarter profit  Oct. 26, but failed to beat the revenue consensus in the earnings report. The Analyst Credit Suisse's Michael Weinstein initiated coverage of NextEra Energy with an Outperform rating and $173...

Boston Scientific Corporation (NYSE: BSX) announced Tuesday after the close a delay to earlier timelines that were established for commercialization of the LOTUS Edge Aortic Valve System in Europe and the U.S. The company had previously looked at reintroducing the product in Europe in the first...

Although ConforMIS Inc (NASDAQ: CFMS) delivered a 1Q top-line beat, the guidance was disappointing. JPMorgan’s Michael Weinstein downgraded the rating for the company from Overweight to Neutral, while reducing the price target from $18 to $8. He cited the reasons as the reduced 2016...

On April 28, Abbott Laboratories (NYSE: ABT) announced the acquisition of St. Jude Medical, Inc. (NYSE: STJ) for $82.50 per share. JPMorgan’s Michael Weinstein downgraded the rating on St. Jude Medical from Overweight to Neutral, while raising the price target from $66.00 to $82.50. The...

Shares of Nevro Corp (NYSE: NVRO) have appreciated 77.14 percent year to date, shooting up almost to their 52 week high on the morning of December 14. J.P. Morgan’s Michael Weinstein has reiterated an Overweight rating on the company, while raising the price target from $67 to $80....

In a report published Monday, JPMorgan analyst Michael Weinstein discussed Johnson & Johnson (NYSE: JNJ)'s upcoming first quarter report, scheduled for Tuesday, April 14. Weinstein noted that he is expecting a largely in-line quarter on the top line given an improved pharmaceutical...